Ankylosing spondylitis
Commentary
Advice on treating rheumatic diseases from a COVID-19 epicenter
Hospital for Special Surgery rheumatologists discuss their approach to caring for patients with rheumatic diseases within their practice during...
Guidelines
ACR gives guidance on rheumatic disease management during pandemic
When COVID-19 is suspected, rheumatic disease patients may continue their hydroxychloroquine but other rheumatic disease treatments may need to be...
From the Journals
Case series suggests biologics, JAK inhibitors safe during pandemic
Investigators saw no increase in hospitalizations versus the general population in New York City.
From the Journals
Sacroiliac bone marrow edema on MRI may be common postpartum
When suspecting axial spondyloarthritis, clinicians may need to wait at least 6 months after delivery to perform an MRI of the sacroiliac joints...
Conference Coverage
Differentiating hypersensitivity reactions to monoclonal antibodies
MAUI, HAWAII – Who to send to the allergist for desensitization.
From the Journals
Financial incentives affect the adoption of biosimilars
Adoption of infliximab biosimilars proceeded more slowly at an academic medical center than at a neighboring VAMC, where financial incentives to...
Feature
‘We’re in great distress here,’ infusion center CMO says
Thrivewell is also deploying a mobile infusion unit to recovered COVID-19 patients who require an infusion for their autoimmune disease.
Conference Coverage
When the going gets tough, ophthalmologists call the rheumatologist
MAUI, HAWAII – Dr. Alvin F. Well describes his approach to treating uveitis, and what to know about teprotumumab, the first treatment for thyroid...
From the Journals
Treatment for RA, SpA may not affect COVID-19 severity
A small study in Italy saw no apparent worsening of COVID-19 symptoms among people treated for RA or spondyloarthritis.
From the Journals
JAK inhibitors may increase risk of herpes zoster
Patients who received Janus kinase (JAK) inhibitors had a 57% increased relative risk of herpes zoster infection.
From the Journals
Rapid shift to adalimumab biosimilars in Denmark contrasts with U.S. experience
The Danish health care system’s shift to adalimumab biosimilars led to substantial decreases in cost.